Please confirm you are human (Sign Up for free to never see this)
← Back to Search
BAP1 (BRCA1-associated Protein 1) Is A Highly Specific Marker For Differentiating Mesothelioma From Reactive Mesothelial Proliferations
Marta Cigognetti, S. Lonardi, S. Fisogni, P. Balzarini, V. Pellegrini, A. Tironi, L. Bercich, M. Bugatti, G. Rossi, B. Murer, M. Barbareschi, S. Giuliani, A. Cavazza, G. Marchetti, W. Vermi, F. Facchetti
Published 2015 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The distinction between malignant mesothelioma and reactive mesothelial proliferation can be challenging both on histology and cytology. Recently, variants of the BRCA1-associated protein 1 (BAP1) gene resulting in nuclear protein loss were reported in hereditary and sporadic mesothelioma. Using immunohistochemistry, we evaluated the utility of BAP1 expression in the differential diagnosis between mesothelioma and other mesothelial proliferations on a large series of biopsies that included 212 mesotheliomas, 12 benign mesothelial tumors, and 42 reactive mesothelial proliferations. BAP1 stain was also performed in 70 cytological samples (45 mesotheliomas and 25 reactive mesothelial proliferations). BAP1 was expressed in all benign mesothelial tumors, whereas 139/212 (66%) mesotheliomas were BAP1 negative, especially in epithelioid/biphasic compared with sarcomatoid/desmoplastic subtypes (69% vs 15%). BAP1 loss was homogeneous in neoplastic cells except for two epithelioid mesotheliomas showing tumor heterogeneity. By fluorescence in situ hybridization, BAP1 protein loss was paralleled by homozygous deletion of the BAP1 locus in the vast majority of BAP1-negative tumors (31/41, 76%), whereas 9/10 BAP1-positive mesotheliomas were normal. In biopsies interpreted as reactive mesothelial proliferation BAP1 loss was 100% predictive of malignancy, as all 6 cases subsequently developed BAP1-negative mesothelioma, whereas only 3/36 (8%) BAP1-positive cases progressed to mesothelioma. On cytology/cell blocks, benign mesothelial cells were invariably positive for BAP1, whereas 64% of mesotheliomas showed loss of protein; all 6 cases showing BAP1 negativity were associated with histological diagnosis of BAP1-negative mesothelioma. BAP1 stain also showed utility in the differential of mesothelioma from most common pleural and peritoneal mimickers, such as lung and ovary carcinomas, with specificity and sensitivity of 99/70% and 100/70%, respectively. Our results show that BAP1 protein is frequently lost in mesothelioma, especially of epithelioid/biphasic subtype and is commonly associated with homozygous BAP1 deletion. BAP1 immunostain represents an excellent biomarker with an unprecedented specificity (100%) in the distinction between benign and malignant mesothelial proliferations. Finding BAP1 loss in mesothelial cells should prompt to immediately reevaluate the patient; moreover, it might be useful in mapping tumor extent and planning surgical resection.
This paper references
The Deubiquitinating Enzyme BAP1 Regulates Cell Growth via Interaction with HCF-1*
Y. Machida (2009)
BAP1 and cancer
M. Carbone (2013)
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
Mesothelioma Epidemiology, Carcinogenesis, and Pathogenesis
H. Yang (2008)
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry
Xue-ying Su (2011)
IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
K. Ikeda (2010)
p53 immunostaining is a highly specific and moderately sensitive marker of malignancy in serous fluid cytology
F. Mayall (1997)
Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma
Y. Takeshima (2009)
p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sections
F. Mayall (1992)
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2
R. Attanoos (2003)
[Guidelines for pathologic diagnosis of malignant mesothelioma--2012 update of the consensus statement from the International Mesothelioma Interest Group].
Riping Chen (2015)
A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability
Shan-Xiang Shen (1998)
Sarcomatoid neoplasms of the lung and pleura.
W. Travis (2010)
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis
M. Takeda (2010)
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study
D. Lucas (2003)
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
P. Cagle (1994)
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.
S. Lagana (2012)
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
F. Hasteh (2010)
The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis
P. Cury (1999)
How useful is GLUT1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas ? An international collaborative study
AN Husain (2014)
Germline mutations in BAP1 impair its function in DNA double-strand break repair.
I. H. Ismail (2014)
Expression and role of GLUT-1, MCT-1 and MCT-4 in malignant pleural mesothelioma
茂木 愛 (2012)
Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update.
N. Ordóñez (2013)
Oncofetal Protein IMP3, a New Diagnostic Biomarker to Distinguish Malignant Mesothelioma From Reactive Mesothelial Proliferation
M. Shi (2011)
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
M. Carbone (2012)
Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium
A. Sato (2010)
Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage.
W. Vermi (2009)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Karen H. Ventii (2008)
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
D. Jensen (1998)
Pleural malignant mesothelioma epidemic: Incidence, modalities of asbestos exposure and occupations involved from the Italian National Register
A. Marinaccio (2012)
Frequent inactivation of the BAP1 gene in epithelioid‐type malignant mesothelioma
Yoshie Yoshikawa (2012)
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data
J. King (2006)
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cells.
H. Minato (2014)
CD147 immunohistochemistry discriminates between reactive mesothelial cells and malignant mesothelioma
C. Pinheiro (2012)
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions
F. Facchetti (2007)
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
The high post‐test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant
J. Aerts (2006)
Immunohistochemical diagnosis of epithelioid mesotheliomas: a critical review of old markers, new markers.
N. Ordóñez (2002)
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
The European mesothelioma epidemic
J. Peto (1999)
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis
A. Dejmek (2000)
Frequent deletion of 3p21.1 region carrying semaphorin 3G and aberrant expression of the genes participating in semaphorin signaling in the epithelioid type of malignant mesothelioma cells.
Yoshie Yoshikawa (2011)
BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity.
H. Nishikawa (2009)
Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition
A. de Reyniès (2014)
Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling
X. Sun (2005)
How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
A. Husain (2014)
The Ubiquitin Carboxyl Hydrolase BAP1 Forms a Ternary Complex with YY1 and HCF-1 and Is a Critical Regulator of Gene Expression
Helen Yu (2010)
Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low‐risk clear cell renal cell carcinoma
R. Joseph (2014)
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
T. Milman (2011)
Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium
M. Ramael (1992)
Tumors of the Serosal Membranes
A. Churg (2006)
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA
D. Henderson (2013)
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
S. Monaco (2011)
Diagnostic usefulness of EMA, IMP3, and GLUT‐1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations
K. Ikeda (2011)
Registro Nazionale dei Mesoteliomi. Quarto Rapporto. Istituto Nazionale per l'Assicurazione contro gli Infortuni sul Lavoro: Roma2012
A Marinaccio (2012)
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
IMP3 and GLUT-1 Immunohistochemistry for Distinguishing Benign From Malignant Mesothelial Proliferations
A. Lee (2013)
Sarcomatoid , desmoplastic , and biphasic mesothelioma
WD Travis (2015)
Anti‐mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms
R. Attanoos (2000)
Germline mutations in BAP1 predispose to melanocytic tumors
T. Wiesner (2011)
A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression
T. Wiesner (2012)
Cytology of the serosal surfaces
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
p16 FISH Deletion in Surface Epithelial Mesothelial Proliferations Is Predictive of Underlying Invasive Mesothelioma
H. Hwang (2014)
Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.
B. Price (2004)
Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma
Y. Kato (2007)
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations
B. Sheffield (2015)
WHO classification of tumours of the lung, pleura, thymus and heart
W. Travis (2015)
This paper is referenced by
Pleura revisited: From histology and pathophysiology to pathology and molecular biology
G. Karpathiou (2019)
Pathological Diagnosis of Mesothelioma
G. Fontanini (2019)
An unusual case of chylothorax
Lauryn A Benninger (2018)
Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
Valeria Maffeis (2019)
Update on Immunohistochemistry for the Diagnosis of Lung Cancer
K. Inamura (2018)
Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia.
M. Yoshimura (2019)
Molecular characterization of diffuse malignant peritoneal mesothelioma
Y. Hung (2020)
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?
H. G. Ozdemir (2020)
Ubiquitin carboxyl-terminal hydrolases: involvement in cancer progression and clinical implications
Y. Fang (2017)
Integrated palliative care of respiratory disease
S. Bourke (2013)
Loss of BAP1 expression is associated with genetic mutation and can predict outcomes in gallbladder cancer
Takashi Hirosawa (2018)
Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
N. Joseph (2017)
Non-infectious Benign Diseases of the Pleura
A. Weissferdt (2020)
Radiation Therapy in Mesothelioma
J. Willmann (2019)
Cell Signaling and Epigenetic Mechanisms in Mesothelioma
B. Mossman (2017)
Apport de l’expression protéique de BRCA1 associated protein 1 (BAP1) dans le diagnostic des mésothéliomes malins diffus pleuraux : une analyse cytologique et histologique comparative sur une série de 50 patients
A. Jaouen (2016)
The epithelioid BAP1‐negative and p16‐positive phenotype predicts prolonged survival in pleural mesothelioma
A. Chou (2018)
Malignant Mesothelioma: Pathology
S. Anttila (2014)
Introductory Chapter: Pathology of the Pleura
J. Stojšić (2020)
Genomic Deletion of BAP1 and CDKN2A Are Useful Markers for Quality Control of Malignant Pleural Mesothelioma (MPM) Primary Cultures
K. Sarun (2018)
Integrated Palliative Care of Respiratory Disease
S. Bourke (2019)
Serous Effusion Cytology
Q. Li (2018)
Improving the Accuracy of Mesothelioma Diagnosis in China
Zhenying Guo (2017)
About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis
M. Mlika (2019)
A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Y. Kinoshita (2018)
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests
T. Hida (2016)
Diagnostic value of BRCA1‐associated protein‐1, glucose transporter‐1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions
S. Önder (2019)
Differential diagnosis of malignant pleural mesothelioma on cytology: a gene expression panel versus BAP1 and p16 tests.
R. Bruno (2020)
Malignant mesothelioma in situ: diagnostic and clinical considerations.
E. Pulford (2020)
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin
A. Bellizzi (2020)See more